Czech National Bank Purchases 4,406 Shares of Stryker Corporation $SYK

Czech National Bank raised its position in shares of Stryker Corporation (NYSE:SYK) by 4.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,207 shares of the medical technology company’s stock after acquiring an additional 4,406 shares during the period. Czech National Bank’s holdings in Stryker were worth $30,919,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new stake in Stryker during the 4th quarter valued at approximately $26,000. Sankala Group LLC acquired a new position in shares of Stryker during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker in the fourth quarter worth $28,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.0%

NYSE SYK opened at $336.91 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a market capitalization of $129.23 billion, a price-to-earnings ratio of 34.91, a PEG ratio of 2.15 and a beta of 0.76. The stock’s 50 day moving average is $319.45 and its two-hundred day moving average is $334.10. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 323,264 shares of company stock worth $100,659,489 in the last quarter. 4.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on SYK shares. Royal Bank Of Canada cut their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Citizens Jmp cut their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Finally, Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.